Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Does hemodialysis affect clopidogrel resistance as measured by VerifyNow P2Y12 test?

Geara AS, Ayoub I, Abi Rached J, Siddique MN, Ghimire P, El-Sayegh S.

Am J Cardiol. 2011 Apr 1;107(7):1103-4. doi: 10.1016/j.amjcard.2011.01.003. No abstract available.

PMID:
21419895
2.

Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays.

Consuegra-Sánchez L, López-Palop R, Cano P, Carrillo P, Picó F, Villegas M, Sanchis J, Kaski JC.

J Thromb Haemost. 2013 Feb;11(2):379-81. doi: 10.1111/jth.12073. No abstract available.

3.

A comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients undergoing percutaneous coronary intervention.

Jang J, Lim J, Chang K, Kim Y, Kim M, Park HI, Kim J, Shin S.

J Clin Lab Anal. 2012 Jul;26(4):262-6. doi: 10.1002/jcla.21515.

PMID:
22811359
4.

Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.

Cuisset T, Frere C, Poyet R, Quilici J, Gaborit B, Bali L, Brissy O, Lambert M, Morange PE, Alessi MC, Bonnet JL.

Arch Cardiovasc Dis. 2010 Jan;103(1):39-45. doi: 10.1016/j.acvd.2009.11.004. Epub 2010 Jan 25.

5.

Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention.

Ahn SG, Lee SH, Sung JK, Kim JY, Yoon J.

Platelets. 2011;22(4):305-7. doi: 10.3109/09537104.2010.525268. Epub 2011 Apr 11. No abstract available.

PMID:
21480769
6.

The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

Thromb Res. 2011 Oct;128(4):352-7. doi: 10.1016/j.thromres.2011.05.008. Epub 2011 May 28.

PMID:
21621250
7.

Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans.

Park KW, Park JJ, Jeon KH, Kang SH, Oh IY, Yang HM, Cho HJ, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS.

Cardiovasc Ther. 2012 Feb;30(1):5-11. doi: 10.1111/j.1755-5922.2010.00249.x. Epub 2010 Dec 6.

PMID:
21129165
8.

Clinical use of clopidogrel.

Sarafoff N, Byrne RA, Sibbing D.

Curr Pharm Des. 2012;18(33):5224-39. Review.

PMID:
22724411
9.

Impact of initial clinical presentation on clopidogrel low response.

Landel JB, Bauters A, Delhaye C, Bonello L, Sudre A, Susen S, Bauters C, Lablanche JM, Lemesle G.

Arch Cardiovasc Dis. 2013 Nov;106(11):593-600. doi: 10.1016/j.acvd.2013.06.050. Epub 2013 Sep 23.

10.

The STIB score: a simple clinical test to predict clopidogrel resistance.

Legrand D, Barbato E, Chenu P, Magne J, Vrolix M, Wijns W, Legrand V; STIB investigators..

Acta Cardiol. 2015 Oct;70(5):516-21. doi: 10.2143/AC.70.5.3110511.

11.

Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department.

Sharma RK, Erickson SW, Sharma R, Voelker DJ, Reddy HK, Dod H, Marsh JD.

Vasc Health Risk Manag. 2013;9:187-93. doi: 10.2147/VHRM.S43909. Epub 2013 May 1.

12.

Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?

Cattaneo M.

J Thromb Haemost. 2012 Mar;10(3):327-36. doi: 10.1111/j.1538-7836.2011.04602.x. Review.

13.

High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study.

Chirumamilla AP, Maehara A, Mintz GS, Mehran R, Kanwal S, Weisz G, Hassanin A, Hakim D, Guo N, Baber U, Pyo R, Moses JW, Fahy M, Kovacic JC, Dangas GD.

JACC Cardiovasc Imaging. 2012 May;5(5):540-9. doi: 10.1016/j.jcmg.2011.12.019.

14.

Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.

Bal Dit Sollier C, Berge N, Boval B, Dubar M, Drouet L.

Thromb Haemost. 2010 Sep;104(3):571-81. doi: 10.1160/TH09-11-0803. Epub 2010 Jul 20.

PMID:
20664906
15.

New anti-platelet agents: the end of resistance?

Kastrati A.

Thromb Res. 2012 Oct;130 Suppl 1:S53-5. doi: 10.1016/j.thromres.2012.08.275. Review.

PMID:
23026663
16.

Latest clinical data on testing for high on-treatment platelet reactivity.

Fileti L, Campo G, Valgimigli M.

Rev Cardiovasc Med. 2011;12 Suppl 1:S14-22. Review.

PMID:
22080983
17.

Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.

Tan GM, Lam YY, Yan BP.

Cardiovasc Ther. 2012 Aug;30(4):e167-73. doi: 10.1111/j.1755-5922.2011.00262.x. Epub 2011 Jul 31. Review.

PMID:
21883998
18.

Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

J Thromb Haemost. 2010 Jan;8(1):37-42. doi: 10.1111/j.1538-7836.2009.03644.x. Epub 2009 Oct 10.

19.

Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients.

Paniccia R, Antonucci E, Maggini N, Miranda M, Gori AM, Marcucci R, Giusti B, Balzi D, Prisco D, Abbate R.

Thromb Haemost. 2010 Aug;104(2):287-92. doi: 10.1160/TH09-12-0832. Epub 2010 May 10.

PMID:
20458439
20.

High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials.

Trenk D, Kristensen SD, Hochholzer W, Neumann FJ.

Thromb Haemost. 2013 May;109(5):834-45. doi: 10.1160/TH12-08-0588. Epub 2012 Dec 13. Review.

PMID:
23238773

Supplemental Content

Support Center